According to Dr. Aiello, anti-VEGF treatments proved to be approximately twice as effective in improving vision and nearly three times more effective in preventing vision loss
from diabetic macular edema than laser treatments.
If left untreated, about a quarter of people with diabetes eventually lose some of their vision
from diabetic macular edema — a condition in which leaking blood vessels cause swelling in the center of the retina.
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss
from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost - effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.
Not exact matches
Regeneron Pharmaceuticals this week reported positive results
from two phase 3 trials of Eylea (aflibercept) injection for
diabetic macular edema (DME).